Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ORIC Oric Pharmaceuticals Inc.

Trading 05-05 13:40:00 EDT

9.26

-0.37

-3.89%

High9.64	Low9.14	Vol782.12K
Open9.41	D1 Closing9.63	Amplitude5.24%
Mkt Cap958.06M	Tradable Cap654.57M	Total Shares103.52M
T/O7.30M	T/O Rate1.11%	Tradable Shares70.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ORIC","market":"US","secType":"STK","nameCN":"Oric Pharmaceuticals Inc.","latestPrice":9.255,"timestamp":1778002798156,"preClose":9.63,"halted":0,"volume":782118,"delay":0,"changeRate":-0.03894080996884735,"floatShares":70726400,"shares":103517562,"eps":-1.47,"marketStatus":"Trading","change":-0.375,"latestTime":"05-05 13:40:00 EDT","open":9.41,"high":9.64,"low":9.135,"amount":7301038.681044,"amplitude":0.05244,"askPrice":9.26,"askSize":55,"bidPrice":9.24,"bidSize":12,"shortable":3,"etf":0,"ttmEps":-1.47,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1778011200000},"marketStatusCode":2,"adr":0,"listingDate":1587700800000,"exchange":"NASDAQ","adjPreClose":9.63,"preHourTrading":{"tag":"盘前","latestPrice":9.5,"preClose":9.63,"latestTime":"09:28 EDT","volume":2301,"amount":22067.008782,"timestamp":1777987707058,"change":-0.13,"changeRate":-0.013499,"amplitude":0.034268},"postHourTrading":{"tag":"盘后","latestPrice":9.58,"preClose":9.63,"latestTime":"19:25 EDT","volume":18732,"amount":180310.0135,"timestamp":1777937119159,"change":-0.05,"changeRate":-0.005192,"amplitude":0.010384},"volumeRatio":0.990332,"impliedVol":0.6584,"impliedVolPercentile":0.1633},"requestUrl":"/m/hq/s/ORIC/wiki","defaultTab":"wiki","newsList":[{"id":"2633942529","title":"Oric Pharmaceuticals Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2633942529","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633942529?lang=en_us&edition=fundamental","pubTime":"2026-05-06 00:04","pubTimestamp":1777997040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ORIC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2026 12:04 ET (16:04 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633485819","title":"ORIC Pharmaceuticals: Buy Rating Backed by Advancing Oncology Pipeline, Phase 3 Prostate Cancer Trial and 2026 NSCLC Data Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2633485819","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633485819?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:15","pubTimestamp":1777983322,"startTime":"0","endTime":"0","summary":"In a report released today, Boris Peaker from JonesTrading maintained a Buy rating on Oric Pharmaceuticals, with a price target of $25.00. Boris Pe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/oric-pharmaceuticals-buy-rating-backed-by-advancing-oncology-pipeline-phase-3-prostate-cancer-trial-and-2026-nsclc-data-catalysts-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/oric-pharmaceuticals-buy-rating-backed-by-advancing-oncology-pipeline-phase-3-prostate-cancer-trial-and-2026-nsclc-data-catalysts-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633591790","title":"Piper Sandler Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633591790","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633591790?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:38","pubTimestamp":1777981083,"startTime":"0","endTime":"0","summary":"In a report released today, Kelsey Goodwin from Piper Sandler maintained a Buy rating on Oric Pharmaceuticals, with a price target of $22.00. Goodw...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633991212","title":"Guggenheim Remains a Buy on Oric Pharmaceuticals (ORIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633991212","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633991212?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:18","pubTimestamp":1777979912,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Bradley Canino reiterated a Buy rating on Oric Pharmaceuticals yesterday and set a price target of $18.00. The company’s shares ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-oric-pharmaceuticals-oric-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-oric-pharmaceuticals-oric-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633124969","title":"Oric Pharmaceuticals (ORIC) Receives a Buy from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2633124969","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633124969?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:18","pubTimestamp":1777979888,"startTime":"0","endTime":"0","summary":"In a report released today, Derek Archila from Wells Fargo reiterated a Buy rating on Oric Pharmaceuticals, with a price target of $25.00. Archila ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oric-pharmaceuticals-oric-receives-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oric-pharmaceuticals-oric-receives-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z3B42.SGD","IE00B19Z3581.USD","BK4585","LU0130102774.USD","LU0868494617.USD","LU1267930490.SGD","LU0029864427.USD","IE0002270589.USD","LU0149725797.USD","LU0980610538.SGD","LU0072461881.USD","LU0256863811.USD","BK4559","LU0289960550.SGD","LU0708994859.HKD","LU2361044865.SGD","LU1201861249.SGD","LU1814569148.SGD","BK4207","LU1280957306.USD","IE00B7SZLL34.SGD","LU0175139822.USD","LU1894683264.USD","LU0211328371.USD","LU0868494708.USD","LU0130517989.USD","LU1069347547.HKD","LU2361044949.HKD","LU1894683348.USD","LU0208291251.USD","LU0314106906.USD","LU0683600562.USD","LU0251131958.USD","LU1791807156.HKD","LU1267930573.SGD","ORIC","LU1363072403.SGD","BK4588","BK4139","LU0128525689.USD","LU1035773651.USD","LU0971096721.USD","LU2361045086.USD","LU0162691827.USD","LU0310800965.SGD","LU0310800379.SGD","LU0052756011.USD","LU0211327993.USD","LU0128525929.USD","LU0942090050.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633775919","title":"Oric Pharmaceuticals price target lowered to $16 from $17 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2633775919","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633775919?lang=en_us&edition=fundamental","pubTime":"2026-05-05 18:39","pubTimestamp":1777977589,"startTime":"0","endTime":"0","summary":"Citi lowered the firm’s price target on Oric Pharmaceuticals (ORIC) to $16 from $17 and keeps a Buy rating on the shares. Published first on TheFly...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-price-target-lowered-to-16-from-17-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-price-target-lowered-to-16-from-17-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633966410","title":"Oric Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633966410","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633966410?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:30","pubTimestamp":1777926658,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryOric Pharmaceuticals Inc ORIC.OQ reported a quarterly adjusted loss of 34 cents per share for the quarter ende","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H291:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633661479","title":"ORIC Pharmaceuticals Q1 EPS $(0.34) Misses $(0.32) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633661479","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633661479?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:29","pubTimestamp":1777926592,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals Q1 EPS $(0.34) Misses $(0.32) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/ORIC","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"ORIC Pharmaceuticals Q1 EPS $(0.34) Misses $(0.32) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633965966","title":"Oric initiates Himalayas-1 Phase 3 trial of rinzimetostat plus darolutamide in mCRPC","url":"https://stock-news.laohu8.com/highlight/detail?id=2633965966","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633965966?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:24","pubTimestamp":1777926256,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals selected 400 mg once-daily rinzimetostat with darolutamide as recommended Phase 3 dose for Himalayas-1, global registrational trial in post-abiraterone metastatic castration-resistant prostate cancer expected to start in 1H 2026.Early results were already presented, supporting a differentiated safety profile and signs of disease control versus standard therapies, positioning program for late-stage development.Another early dataset in patients previously treated with androgen receptor inhibitors was also presented, showing durability that could extend benefit from hormonal therapy in a setting where responses are typically short-lived.Program update is expected in 2H 2026, with cash and investments of USD 419.7 million projected to fund operations into 2H 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL7FqYkq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633196548","title":"Oric Q1 FY26 net loss widens to $35.77 million; R&D expenses rise to $31.44 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633196548","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633196548?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:13","pubTimestamp":1777925597,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals posted a Q1 net loss of $35.77 million, widening from $30.02 million a year earlier, while loss per share narrowed to $0.34 from $0.42.Operating loss widened to $39.62 million as R&D expenses climbed to $31.4 million from $24.6 million; G&A held roughly flat at $8.2 million.Cash, cash equivalents and investments totaled $419.7 million, including $59.9 million of net proceeds raised under its ATM program, with runway expected into 2H 2028.Selected rinzimetostat 400 mg once daily as recommended Phase 3 dose with darolutamide, targeting initiation of Himalayas-1 Phase 3 registrational trial in post-abiraterone mCRPC in 1H 2026.Completed enrollment in enozertinib Phase 1b monotherapy in first-line EGFR exon 20 insertion NSCLC, with several enozertinib clinical updates expected in 2H 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL8srFy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","IE00B64PRP62.GBP","BK4588","BK4139","IE00B3QW5Z07.USD","SG9999014021.USD","LU2210149790.SGD","IE00BKPKM429.USD","LU2095319765.USD","NDAQ","BK4585","BK4112","SG9999014013.SGD","SG9999014039.USD","ORIC","IE00BN0W2T93.GBP","LU2210150020.SGD","SG9999014005.SGD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633996582","title":"BRIEF-ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633996582","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633996582?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:05","pubTimestamp":1777925148,"startTime":"0","endTime":"0","summary":"BRIEF-ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million\n\n\nMay 04 (Reuters) - ORIC Pharmaceuticals Q1 income from operations USD -39.619 million.\n\nQ1 net income USD -35.767 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nPLXCABFA8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633896321","title":"Oric Pharmaceuticals Q1 Operating Expenses USD 39.619 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633896321","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633896321?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:05","pubTimestamp":1777925103,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nPLXCABFA8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633668969","title":"ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633668969","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633668969?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:05","pubTimestamp":1777925100,"startTime":"0","endTime":"0","summary":"Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026 Reported rinzi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3287132/0/en/ORIC-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Operational-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AR","BK4139","ORIC","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632647415","title":"ORIC Pharma grants 216,000 stock options, 35,000 RSUs to new employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2632647415","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632647415?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:30","pubTimestamp":1777667433,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals issued inducement equity awards dated May 1, 2026 for four new non-executive employees hired in April 2026.Grants comprised 216,000 non-qualified stock options, plus 35,000 restricted stock units.Options carry an exercise price set at closing price of Oric common stock on grant date.Option vesting schedules 25% at first anniversary of grant date, then monthly over next 36 months.Restricted stock units vest in three equal annual installments starting first anniversary of grant date.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL2LJZcG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014013.SGD","NDAQ","LU2095319765.USD","BK4139","SG9999014005.SGD","BK4588","SG9999014021.USD","IE00BN0W2W23.USD","BK4112","LU2210150020.SGD","SG9999014039.USD","IE00BKPKM429.USD","ORIC","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632731647","title":"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632731647","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632731647?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:30","pubTimestamp":1777667400,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May  01, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/01/3286230/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632644739","title":"U.S. Earnings Preview: After Market Close May 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2632644739","media":"Dow Jones","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632644739?lang=en_us&edition=fundamental","pubTime":"2026-05-02 03:31","pubTimestamp":1777663860,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.The following companies are among those expected to report their latest financial results after the market closes.AnaptysBio Inc.'s first-quarter EPS is forecast at a loss of 72 cents, compared with a loss of $1.28 in the prior-year period.Oric Pharmaceuticals Inc.'s first-quarter EPS is forecast at a loss of 31 cents, compared with a loss of 42 cents in the prior-year period. Adjusted EPS is forecast at a loss of 32 cents.Biomea Fusion Inc.'s first-quarter EPS is forecast at a loss of 28 cents, compared with a loss of 80 cents in the prior-year period. Adjusted EPS is forecast at a loss of 23 cents.Generated from Dow Jones Calendar Live with data from Dow Jones and Factset.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","ANAB","BK4139","ORIC","BK4539","BMEA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631336625","title":"Oric Pharmaceuticals announces annual shareholder meeting notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2631336625","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631336625?lang=en_us&edition=fundamental","pubTime":"2026-04-29 04:05","pubTimestamp":1777406705,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals schedules 2026 annual stockholder meeting in virtual format on June 18, 2026.Votes set on election of two Class III directors.Ballot includes ratification of KPMG as independent registered public accounting firm for fiscal 2026.Stockholders to consider amended and restated 2020 Equity Incentive Plan.Advisory votes planned on executive compensation, including preferred frequency for future say-on-pay votes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 28, 2026, and is solely responsible fo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL4Fdp3w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629054154","title":"A Look At ORIC Pharmaceuticals (ORIC) Valuation After New Rinzimetostat AACR Prostate Cancer Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2629054154","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629054154?lang=en_us&edition=fundamental","pubTime":"2026-04-22 02:08","pubTimestamp":1776794935,"startTime":"0","endTime":"0","summary":"Why the AACR data on rinzimetostat is on investors’ radar\nORIC Pharmaceuticals (ORIC) shares are in focus after the company highlighted new preclinical data for rinzimetostat at the 2026 AACR Annual Meeting, centered on prostate cancer models that include treatment resistant disease.\nSee our latest analysis for ORIC Pharmaceuticals.\nORIC’s latest AACR posters on rinzimetostat arrive after a strong year to date, with a 33.29% year to date share price return and a 123.61% 1 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/a-look-at-oric-pharmaceuticals-oric-valuation-after-new-rinz","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/a-look-at-oric-pharmaceuticals-oric-valuation-after-new-rinz","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ORIC","BK4139","DCF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628784828","title":"Oric Pharmaceuticals presents Rinzimetostat preclinical data at AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=2628784828","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628784828?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:10","pubTimestamp":1776456655,"startTime":"0","endTime":"0","summary":"ORIC Pharmaceuticals (ORIC) “announced the presentation of multiple poster presentations at the 2026 American Association for Cancer Research Annua...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-presents-rinzimetostat-preclinical-data-at-aacr-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-presents-rinzimetostat-preclinical-data-at-aacr-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628781474","title":"Oric presents preclinical AACR data backing rinzimetostat in prostate cancer models","url":"https://stock-news.laohu8.com/highlight/detail?id=2628781474","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628781474?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:07","pubTimestamp":1776456465,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals disclosed new preclinical data supporting rinzimetostat  in prostate cancer, with presentations scheduled for the 2026 AACR Annual Meeting.Studies indicate PRC2 activity emerges early in prostate cancer and persists through progression, supporting PRC2 inhibition as a potential therapeutic strategy.Rinzimetostat paired with androgen receptor pathway inhibition showed antitumor effects across models spanning castration-sensitive and castration-resistant disease.Additional preclinical work suggests EED targeting could help address resistance seen with some EZH2-directed approaches, with rinzimetostat retaining activity in select resistance settings.Oric also highlighted formulation and pharmacology attributes that could support oral dosing and clinical use versus comparator PRC2 inhibitors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL9b09S8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oricpharma.com","stockEarnings":[{"period":"1week","weight":-0.055},{"period":"1month","weight":0.0832},{"period":"3month","weight":-0.1245},{"period":"6month","weight":-0.2221},{"period":"1year","weight":0.6984},{"period":"ytd","weight":0.1773}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0948},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.0597},{"period":"1year","weight":0.2669},{"period":"ytd","weight":0.0529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.039993},{"month":2,"riseRate":0.5,"avgChangeRate":-0.014475},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.092137},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.173514},{"month":5,"riseRate":0.571429,"avgChangeRate":0.064091},{"month":6,"riseRate":0.666667,"avgChangeRate":0.141043},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.000511},{"month":8,"riseRate":0.666667,"avgChangeRate":0.090659},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.048915},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.0811},{"month":11,"riseRate":0.666667,"avgChangeRate":0.167402},{"month":12,"riseRate":0.5,"avgChangeRate":0.06155}],"exchange":"NASDAQ","name":"Oric Pharmaceuticals Inc.","nameEN":"Oric Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oric Pharmaceuticals Inc.,ORIC,Oric Pharmaceuticals Inc.股票,Oric Pharmaceuticals Inc.股票老虎,Oric Pharmaceuticals Inc.股票老虎国际,Oric Pharmaceuticals Inc.行情,Oric Pharmaceuticals Inc.股票行情,Oric Pharmaceuticals Inc.股价,Oric Pharmaceuticals Inc.股市,Oric Pharmaceuticals Inc.股票价格,Oric Pharmaceuticals Inc.股票交易,Oric Pharmaceuticals Inc.股票购买,Oric Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}